Table 1 Main clinical characteristics and clinical outcome of patients with advanced cancer treated with neo-T therapy
Patient No. | HLA-A | Cancer type | Stage at diagnosis | Sites of tumor | Prior therapies* | ECOG PS | Neo-T infusion (times) | Response (duration months) | Lymphodepletion (dose) |
|---|---|---|---|---|---|---|---|---|---|
C001 | 0201;1102 | Melanoma | IV | Backside, lymph nodes, shoulder | Surgery,>2 lines of CT | 1 | 2 | NA/ withdrawn | N |
C018 | 0101;1101 | ICC | IV | Liver, lymph nodes | Surgery, > 2 lines of CT | 1 | 3 | NA/ withdrawn | N |
C003 | 1101;1102 | Melanoma | IV | Hip, lymph nodes, penis | Surgery,>2 lines of CT | 1 | 2 | PD | N |
C004 | 1101;1102 | Melanoma | IV | Backside, bone, lung, kidney | Surgery,>2 lines of CT | 0 | 8 | PR (15) | N |
C020 | 0201;3303 | Melanoma | IV | lymph nodes, adrenal gland | Surgery, >2 lines of CT and PD-1 | 1 | 15 | PR(27) | N |
C005 | 0201;0203 | Melanoma | IV | Foot, bone, lymph nodes | Surgery, > 2 lines of CT | 1 | 8 | PR(8) | Low |
C008 | 1101;0207 | Melanoma | IV | Vulva, lymph nodes, lung | Surgery, > 2 lines of CT | 0 | 3 | PD | Low |
C012 | 1101;3303 | Colorectal cancer | IV | Colon, uterus, lymph nodes, hilar | Surgery, RT, 2 lines of CT | 1 | 6 | SD (4) | Low |
C013 | 0206;1101 | Melanoma | IV | Foot, lymph nodes | Surgery, 2 lines of CT | 1 | 6 | SD (4.37) | High |
C015 | 0201;1101 | Melanoma | IV | Thumb, lymph nodes | Surgery, 2 lines of CT | 1 | 6 | SD (4) | High |
C017 | 1101;1101 | Melanoma | IV | Shoulder, lymph nodes | Surgery, 2 lines of CT | 1 | 2 | PD | High |
